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Current understanding of the pathogenesis of chronic obstructive pulmonary disease (COPD), a
source of substantial morbidity and mortality in the United States, suggests that chronic inflammation
leads to the airways obstruction and parenchymal destruction that characterize this condition.
Environmental factors, especially tobacco smoke exposure, are known to accelerate longitudinal
decline of lung function, and there is substantial evidence that upregulation of inflammatory
pathways plays a vital role in this process. Genetic regulation of both inflammatory responses and
anti-inflammatory protective mechanisms likely underlies the heritability of COPD observed in family
studies. In alpha-1 protease inhibitor deficiency, the only genetic disorder known to cause COPD,
lack of inhibition of elastase activity, results in the parenchymal destruction of emphysema. Other
genetic polymorphisms have been hypothesized to alter the risk of COPD but have not been
established as causes of this condition. It is likely that multiple genetic factors interacting with each
other and with a number of environmental agents will be found to result in the development of
COPD. Key words: air pollution, alpha-1 antitrypsin, environment, genetics, lung disease, obstructive,
occupational diseases. - Environ Health Perspect 108(suppl 4):733-742 (2000).
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Tobacco smoking and occupational dust
exposure are environmental risk factors for
the development ofchronic obstructive pul-
monary disease (COPD). Only a minority of
exposed persons, however, develops disabling
COPD; this does not appear related only to
cumulative exposure. At least one genetic dis-
order, homozygous alpha-i protease inhibitor
(API) deficiency, is known to cause COPD;
recent reports suggest that other genetic fac-
tors may also predispose to this condition.
These observations suggest genetically deter-
mined characteristics, particularly those influ-
encing the modulation of inflammatory
injury, likely interact with environmental fac-
tors in the pathogenesis ofCOPD. The envi-
ronmental and genetic risk factors for
COPD, and the interaction between them,
are the focus ofthis review.
Definition and Pathophysiology
ofCOPD
Chronic obstructive pulmonary disease affects
more than 10% ofthe U.S. adult population
(1,2). It is the fourth leading cause ofdeath in
the United States, accounting for over
100,000 deaths per year, and it is the second
leading diagnosis for Social Security disability
payment recipients (3). COPD can be defined
as chronic and mostly irreversible airflow limi-
tation; conditions such as obstructing lesions
ofthe central airways and bronchiectasis or
cystic fibrosis are specifically excluded (4).
Chronic bronchitis, defined as chronic
mucous hypersecretion leading to productive
cough (4), often coexists with chronic airflow
obstruction and is generally considered part of
the spectrum ofCOPD. Most ofthemorbidity
and mortality caused by COPD, however,
results from the chronic airflow obstruction
and associated gas exchange and hemody-
namic abnormalities rather than from the
mucous hypersecretion (5,6). The primarily
irreversible airflow limitation ofCOPD dis-
tinguishes it from asthma, which is character-
ized, at least in its early stages, by variable and
largely reversible airflow limitation.
The defining physiologic characteristic of
COPD is airflow obstruction on spirometry,
i.e., a reduction in both FEV1 (the forced
expiratory volume in 1 sec) and the
FEV1/FVC (forced vital capacity) ratio. The
airflow obstruction develops gradually and
progressively over many years (7). The even-
tual development ofdisabling COPD may
result both from processes affecting lung
growth and development in early life and
from processes affecting longitudinal pul-
monary function decline in adulthood (8,9).
As the chronic airflow obstruction ofCOPD
progresses, it may be accompanied by hyper-
inflation of the chest (physiologically mea-
sured as an increased total lung capacity) due
to both gas trapping (physiologically mea-
sured as an increased residual volume) and
loss ofelastic recoil. These changes may even-
tually put the muscles of respiration at a
mechanical disadvantage, with the resultant
respiratory muscle dysfunction further wors-
ening dyspnea, the cardinal symptom of
COPD, and compromising functional status.
Progressive worsening ofventilatory function
ultimately leads to impaired gas exchange,
with resultant hypoxemiaandhypercapnia.
The histopathologic changes underlying
the chronic airflow obstruction of COPD
include both pulmonary emphysema and
inflammatory disease of the small airways
(10). Emphysema is defined as abnormal
enlargement ofthe alveolar airspaces caused
by the destruction ofthe alveolar walls. This
parenchymal destruction results in the reduc-
tion in alveolar attachments tethering open
the bronchioles and the obliteration offunc-
tional alveolar-capillary units for gas
exchange. In addition to emphysema, lung
tissue from patients with COPD shows
inflammation of the small airways (i.e., the
bronchi with a diameter less than 2 mm and
the bronchioles), with increased numbers of
macrophages and neutrophils, goblet cell
metaplasia, mucus plugging, and fibrosis.
The loss ofradial traction on the peripheral
airways, due to the destruction of alveolar
attachments, and the thickened bronchial
walls, due to bronchiolitis, result in reduc-
tion in the radius ofthe airways and a conse-
quent increase in airways resistance. There
has been controversy about the relative con-
tributions ofparenchymal and airways dis-
ease to the airflow obstruction of COPD
(11,12), although these two abnormalities
are not independent inasmuch as the degree
ofsmall airways disease has been associated
with the loss ofalveolar attachment (13,14).
Although it seems clear that emphysema is
often the major histopathologic abnormality
for patients with severe COPD, small airways
disease probably makes an important contri-
bution and may be the major pathologic
abnormality in some patients.
The cellular and molecular mechanisms
involved in the development of the airflow
obstruction of COPD are not fully under-
stood, and substantial heterogeneity in the
pathogenesis of COPD likely exists. A
model for understanding the development of
this disease has emerged, however, from
investigations of the major environmental
risk factor for COPD (tobacco smoking)
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and ofthe most clearly understood genetic
risk factor (API deficiency). In this model of
COPD pathogenesis, the maintenance of
healthy lung structure and function depends
on the ability ofhomeostatic mechanisms to
protect the airways and lung parenchyma
from both environmental insults and the
inflammatory responses to these insults (10).
Chronic airflow obstruction can develop
because ofa high degree ofchronic inflam-
mation or other injurious process, a defi-
ciency in protective mechanisms, or both.
Lung antiproteases, which modulate prote-
olytic enzymes released by inflammatory
cells and thereby prevent damage at sites of
inflammatory response, appear to be crucial
in this balance (10,15), as discussed below.
Antioxidants and other less well understood
protective mechanisms mayalso be important
in preserving normal lung function in the
face ofa lifetime ofexposure to potentially
injurious environmental factors.
Environmental Risk Factors
A variety ofenvironmental factors have been
associated, both positively and negatively,
with changes in lung function (Table 1).
Myriad exposures, including workplace,
atmospheric, domestic, dietary, and others,
play putative roles in altering lung function.
Those exposures, and the hypothesized mech-
anisms through which they impact lung func-
tion, are reviewed below.
Tobacco smoking is the best-documented
environmental cause of chronic airflow
obstruction and is implicated in more than
Table 1. Environmental factors influencing the risk of
COPD.
Agent Established Suspected
Tobacco Active smoking Environmental
Biologic Grain
dusts
Inorganic Silica (gold and
dusts coal mining)
Fumes,
gases
Pollution
Dietary
factors
tobacco smoke
Cotton
Cork/wood/paper
Chalk
Talc
Metal
Chlorine
SO2
H2S, styrene, polyvinyl
chloride/methyl
Methacrylate
Particulate
NO2
S02
03
Biologiccooking fuels
Antioxidant vitamins,
especiallyA, C, E
(appearto beprotective)
Linoleic acid
Fish oils (appearto be
protective)
Ethanol (effectmixed)
90% ofCOPD cases (16). In cross-sectional
surveys, smoking history is strongly associated
with chronic respiratory symptoms, diagnosed
chronic bronchitis and emphysema, and
obstructive pulmonary function abnormalities
(9). Cohort studies have revealed that adult
smokers experience faster longitudinal pul-
monary function decline than nonsmokers
(7,17) and that this accelerated decline returns
to the normal rate ofaging-related decline fol-
lowing smoking cessation (9,18), even ifthe
cessation is intermittent (19). In addition,
smoking has an adverse impact on lung func-
tion and growth and on the peak pulmonary
function attained among those who take up
the habit early. Smoking teenagers experience
a reduced rate oflung function growth, and
young adult smokers experience an earlier
onset ofpulmonary function decline from the
plateau ofmaximal function achieved in the
third decade oflife (20).
The mechanisms by which tobacco smok-
ing causes COPD have been the subject of
considerable investigation. Substantial evi-
dence suggests the accelerated decline oflung
function in cigarette smokers results from
smoke-induced inflammatory processes.
Inflammation begins with an increased num-
bers ofmacrophages in the first- and second-
generation respiratory bronchioles, where
centrilobular emphysema begins (21).
Ultimately, it extends throughout the
bronchial tree, with the macrophage predomi-
nance ofthe smallest airways changing to lym-
phocyte predominance in medium and large
airways (22-25). The lungs ofcigarette smok-
ers (26-29), as well as the peripheral blood,
contain markedly elevated numbers of neu-
trophils, and blood leukocyte count correlates
with the level and rate ofdedine ofFEV, and
FVC after adjustment for smoking status
(30,31). Centrilobular emphysema and small
airway disease, both ofwhich are important in
the pathophysiology ofairflow obstruction
(32), appear to be the result ofsmall airways
inflammation.
Neutrophils and macrophages produce,
respectively, human neutrophil elastase
(HNE) and metalloelastases; these proteolytic
enzymes have been implicated in the
parenchymal destruction that results in
emphysema. Individuals withseveredeficiency
ofAPI, the major inhibitor ofHNE activity,
experience premature development ofemphy-
sema (10), as discussed in more detail below.
Elastase (33,34) and elastase-API complexes
(35) are found in higherconcentrations in the
bronchoalveolar lavage fluid of smokers.
The plasma ofCOPD patients contains ele-
vated levels ofelastin-derived peptides com-
pared with that of nonsmokers (36,37).
Intratracheal instillation ofproteases with
elastolytic activity provides an animal model
for emphysema (38). Proteases and protease
inhibitors may also play a role in the patho-
genesis ofsmall airway disease. In addition to
the degradation ofairway elastin, HNE and
API have, respectively, pro- and anti-inflam-
matory effects (39,40). Increased elastin
degradation has been observed in smokers
with rapid decline in lung function, an effect
seen equally in subjects with predominantly
emphysema and those with predominantly
airwaydisease (41).
Oxidative injury may also play an impor-
tant role in the pathogenesis ofCOPD (42).
Such injury, resulting from an imbalance
between free radicals and protective mecha-
nisms, can alter the protein conformation of
protease inhibitors and reparative enzymes,
injure cell membranes, and result in mutage-
nesis. Free radicals appear in the lung by
inhalation from the environment orby release
from inflammatory cells. Tobacco smoke
contains a heavy oxidative burden for the
lungs, both in the gas phase and in the tar
components (43), and causes a transient
decline in the antioxidant capacity 1 hr after
smoking a single cigarette (44,45). Both cur-
rent smoking and COPD exacerbations are
associated with increased levels ofmarkers of
oxidative stress and decreased levels ofserum
antioxidants (44,45). Depletion ofthe buffer
against free radicals, either as a result of a
heavy free radical burden or of a decreased
antioxidant capacity, may alter the
protease/antiprotease balance by inactivation
ofantiproteases (46), thereby contributing to
thepathogenesis ofCOPD.
Passive exposure to environmental
tobacco smoke (ETS) has been hypothesized
to be a risk factor for the development of
COPD, but this question has not been
answered with certainty. Dose-response
curves in smokers, measured in terms of
pack-years and reduction in FEV1, suggest
that the estimated ETS exposure of non-
smokers living and working with smokers
may be sufficient to contribute to the devel-
opment ofairflow limitation (47). The com-
position of unfiltered sidestream tobacco
smoke differs in component concentrations
from that ofsmoke inhaled directly during
active smoking, as it contains higher concen-
trations ofsome toxins (43,47). Studies of
airflow obstruction and ETS in adults are
complicated by the difficulties ofassessing
lifetime cumulative ETS exposure, account-
ing for other respiratory irritants, and ascer-
taining any active smoking in the past.
Evidence definitivelylinking ETS exposure to
chronic airflow obstruction in adults is lack-
ing because ofmethodologic difficulties with
existing studies (47,48). There is a consensus,
however, that passive exposure is associated
with reduced pulmonary function in
children. A longitudinal study by Tager et al.
(49) demonstrated a 10.7% reduction in
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FEV, among children with a parent that
smoked compared to children of a non-
smoker. It has been estimated that ETS expo-
sure in childhood results in a 0.5%
FEV1/year decrease in growth ofFEV1 (50).
This reduction ofmaximally attained func-
tion is hypothesized to predispose to impair-
ment ofpulmonaryfunction in later life (51).
Occupational exposure to biologic dusts
has been established as a risk factor for
COPD (52). Grain dust exposure has been
linked to chronic airflow obstruction in both
cross-sectional (53-59) and longitudinal
(60,61) studies, an association that appears to
be independent of the effects of tobacco
smoking. The chronic airflow obstruction
caused by grain dust exposure does not
appear to be associated with either airway
hyperreactivity or allergy to grain constituents
(62-64). Cotton dust exposure in the work-
place has been reported to be associated with
accelerated longitudinal lung function decline
(65), but not all studies confirm these find-
ings (66). Although acute byssinosis ofcotton
dust appears to be caused by the stimulation
ofendotoxin-mediated inflammatory mecha-
nisms, it is not clear that endotoxin is respon-
sible for the chronic airflow obstruction
caused by long-term cotton dust exposure.
The longest cohort study ofcotton workers
demonstrated an excess longitudinal decline
ofFEVI, compared to silkworkers, most pro-
nounced in the earlyyears ofexposure; loss of
pulmonary function was independent ofesti-
mated exposure to inhaled endotoxin (65).
Other workplace biologic dusts implicated in
the development ofchronic airflow obstruc-
tion include cork (67), wood (68), sugar (69),
and paper dusts (70).
Exposure to certain inorganic dusts in
mining and other occupations has also been
shown to be a risk factor for the development
ofchronic airflow obstruction independent of
smoking and pneumoconiosis (71-73). A
meta-analysis (74) ofstudies ofcoal and gold
miners demonstrated that airflow obstruction
was common, more so in gold miners than
coal miners. Silica has been implicated in the
development ofairflow obstruction (75) and
the difference between gold miners and coal
miners may be the result ofhigher silica expo-
sure in the former group. Occupational chalk
dust (69) and talc (76) exposure have also
been reported to be associated with chronic
airflow obstruction.
Although the mechanisms by which
biologic and inorganic dusts lead to chronic
airflow obstruction are not fully understood,
many ofthe same mechanisms underlying the
development of airflow obstruction from
tobacco exposure may be involved. Particle
deposition in the small airways may induce
inflammatory responses, which lead to chronic
airway changes as well as the development of
centrilobular emphysema, as described above
in relation to tobacco smoke. Dust-exposed
groups have been noted to have goblet cell
metaplasia and fibrosis ofthe membranous
bronchioles beyond that seen in smokers (77).
These changes were not seen in other portions
ofthe bronchial tree.
Occupational exposure to chemical fumes
and gases has also been linked to chronic air-
flow obstruction. Metal fumes, a product of
metal working in a variety ofindustries, are
associated with impairment oflung function.
Welders and those exposed to metal fumes
have been noted to have a lower FEV,
(78-82), and the duration ofexposure is sig-
nificantly related to the reduction of lung
function (82). Indirect measures ofmetal
buildup in the lungs correlate with the sever-
ityoflung function impairment (78).
Chlorine in various forms is used in many
industries and frequently appears with other
irritant gases. Pulp and paper mill workers,
frequently exposed to chlorine and SO2 gases,
have been reported to have a high prevalence
ofchronic airflow obstruction (70,79,83,84).
The degree ofairflow limitation is directly
related to the degree ofexposure, and there is
at least an additive effect ofsmoking (84,85).
Chlorine bleach, which frequently induces res-
piratory symptoms, has also been associated
with a decline in lung function (70), even
with minimal historyoftobacco use (84).
Chronic airflow obstruction has also been
reported in association with long-term expo-
sure to H2S (86), styrene and methyl
methacrylate (87), and polyvinyl chloride
(88). Fiberglass and modern insulation mate-
rials have inconsistent impact on airflow
(80,89). For these various gases and fumes
encountered in the workplace, the molecular
and cellular mechanisms leading to chronic
airflow obstruction remain uncertain,
although direct chemical injury to the airway
epithelium may be the initial event in the
pathogenesis ofairflow obstruction.
Outdoor air pollution is a hypothesized
but unproven risk factor for the development
ofCOPD (90). Although the relative inde-
pendent contribution ofindividual pollutants
remains uncertain (91), studies ofthe acute
effects ofair pollution suggest that episodic
increases in particulate matter (92-95), NO2
(95,96), SO2 (95,97,98), and ozone
(92,94-96,99,100) maycause increased respi-
ratory symptoms and hospitalizations among
persons with COPD. Less is known about the
long-term effects of air pollution on pul-
monary function. Although some cross-
sectional studies have revealed lower mean
pulmonary function levels and a higher
prevalence of airflow obstruction among
adults living in more polluted communities
(101-105), other studies revealed no such
differences between communities (106,107).
Studies ofair pollution and lung function in
children revealed lower levels oflung function
(108) in children living in communities with
higher levels ofNO2, 03-, and particulate
matter. The relation between lung function
and SO2 in children is less clear (108). Living
in close proximity to a major point source of
industrial emissions has been reported to be a
risk factor for pulmonary functional impair-
ment amongchildren (109).
Cohort studies suggest that the rate of
longitudinal lung function decline in adults is
related to ambient air pollution levels (105).
These studies, however, must be interpreted
with caution because ofpotential imprecision
in estimating pollution exposure as well as
possible confounding factors. The quantita-
tive impact ofparticular pollutants on pul-
monary function is not fully understood, but
dose-response relationships have been
demonstrated in several studies (103,110),
further suggesting an impact ofair pollution
on long-term lung function.
The combustion ofheating and cooking
fuels in indoor environments leads to the pol-
lution of indoor air with respirable particles,
nitrogen dioxide, and other pollutants.
Although the contribution of these indoor
pollutants to the risk ofdeveloping COPD is
difficult to quantitate, several studies suggest
a relation between indoor fuel combustion
practices and COPD risk (111-115).
Exposure to indoor air pollution caused by
fuel combustion is greater in poorer nations,
and the potential health impact may vary
accordingly.
The environment is not always inhos-
pitable; some factors may help preserve pul-
monary function and prevent COPD. The
role ofdiet in the pathogenesis oflung disease
is not clear, but as our understanding ofthe
pathogenesis ofCOPD evolves, the potential
role ofdiet increases. Antioxidant vitamins
(including C and E) may provide a protective
benefit, but the evidence remains controversial
(116,117). Vitamin E treatment ofchildren of
smokers reduced thesusceptibility to red blood
cell peroxidation in vitro (118). Certain fatty
acids that affect arachidonic acid metabolism,
such as linoleic acid, may worsen pulmonary
function (119), whereas intake ofothers (such
as fish oils) may be protective (120,121), but
the effects ofthese dietary factors were modest.
Investigations into the effects ofethanol have
demonstrated mixed results. Cross-sectional
analysis ofan ongoing cohort study demon-
strated no difference between the pulmonary
function ofheavy drinkers once adjustments
were made for confounding factors (122).
Others have found a small protective effect
(123), even with moderate alcohol consump-
tion (119). Any impact ofalcohol on airflow
obstruction, once adjusted for smoking status,
is likelyto be modest.
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Vitamin A and its derivatives represent an
especially promising venue of research.
Massaro and Massaro (124) observed that
rodents with elastase-induced emphysema
treated with vitamin A derivatives had reversal
ofthe injury pattern, nearly normalizing all
measured indices ofemphysema. In humans,
a small study noted that COPD patients had
low vitamin A status, independent ofsmok-
ing, and that treatment with vitamin A
reversed airways obstruction (125). Further
studyofthe effects ofvitamin Aderivatives on
pulmonaryemphysema is ongoing.
Because inflammation plays a key role in
the pathogenesis ofCOPD, it is possible that
chronic or recurrent infections during adult-
hood result in the development or progres-
sion ofthis condition. This hypothesis, which
was advanced by British investigators in the
1960s and came to be known as the "British
hypothesis," has not been supported by epi-
demiologic investigations (126). Published
data do suggest that viral lower respiratory
infections during childhood may predispose
to impairment ofpulmonary function in later
life, possibly thereby increasing the risk of
COPD (127).
Genetic Factors
A number ofstudies demonstrate a strong
familial correlation ofpulmonary function
measurements (128-137). The degree ofcor-
relation ofFEV, or FVC, adjusted for age,
smoking habits, and body habitus, has been
reported to be in the range of0.11-0.40 for
relatives with 50% genetic identity, with val-
ues typically between 0.20 and 0.25
(132-137). Using path analysis to estimate
the relative contributions ofenvironmental
and genetic factors in determining level of
lung function, two groups concluded that
42-45% ofFEV, variability was due to heri-
table factors (129,134). These heritability
estimates are consistent with the finding of
Redline et al. (132) that the correlation of
FEV1 was 0.71 among 252 adult mono-
zygotic twins. Two studies that used segrega-
tion analysis revealed a pattern of familial
correlation ofpulmonary function consistent
with a polygenic, rather than a single major
Mendelian gene, mode oftransmission; these
models, however, could not exclude familial
environmental rather than genetic factors
(135,136). Rybicki et al. (133) examined 85
COPD families and 56 non-COPD families
for evidence ofMendelian transmission in the
expression ofFEVI, and found evidence ofa
co-dominant major gene among the COPD
families but not among non-COPD families.
Although these studies suggest a role for
genetic factors in determining airflow, most
describe lung function in generally healthy
subjects, and their relevance to clinical
COPD is uncertain.
Several studies have provided direct
evidence of familial clustering of COPD
(138-141). These studies observed a higher
prevalence of COPD among relatives of
COPD patients than among relatives ofcon-
trol subjects without lung disease. Among
smoking siblings ofCOPD patients, the rela-
tive risk ofchronic airflow obstruction was in
the range of2 (139) to 4 (140) compared to
smokers without a family history ofCOPD.
Thus, multiple studies in diverse populations
consistently have shown strong evidence for
heritability of lung function and familial
aggregation of COPD after adjustment for
smoking status, and it appears likely that
multiplegenes are involved.
API deficiency is the only known genetic
disorder unequivocally implicated as a cause
ofemphysema, although only a small propor-
tion ofCOPD cases can be attributed to this
condition. API, an antiprotease that inhibits
the activity ofneutrophil elastase and other
proteolytic enzymes, is a serum protein pri-
marily synthesized in the liver, mononuclear
phagocytes, neutrophils, bowel, and kidney
(142,143). The gene encoding API, located
on chromosomal segment 14q32.1, is highly
pleomorphic, and over 75 distinct alleles have
been described (144. The Pi-M allele and its
subtypes are the most common, with a gene
frequency ofapproximately 900 in 1,000;
persons with Pi-MM genotype have normal
serum levels ofnormally functioning API.
The Pi-Z allele has a point mutation in
exon V that impairs secretion ofsynthesized
API protein (144), and Pi-ZZ homozygotes
have extremely low serum levels ofnormally
functioning API. The Pi-ZZ genotype is the
most common genotype among persons with
severe API deficiency. The Pi-S allele is asso-
ciated with reduced serum levels ofAPI but
to a lesser extent than Pi-Z, and persons with
the Pi-SS genotype have serum API levels
intermediate between those ofpersons with
Pi-MM and Pi-ZZ. Nonexpressing null alle-
les are associated with the absence ofAPI syn-
thesis, and the Pi-null null and Pi-Z null
genotypes are also associated with severe API
deficiency. The API phenotype, assessed by
the distinct electrophoretic patterns associated
with different alleles, is often used as a
surrogate forgenotype.
Persons with severe API deficiency (usu-
ally Pi-ZZ, rarely Pi-Z null or Pi-null null)
often develop severe emphysema at a rela-
tively early age, and this is the major cause of
morbidity and mortality in this condition
(145). Pulmonary development and growth
in early life appear normal, and lung function
remains in the normal range in adolescence
and the beginning ofyoung adulthood. Early
in adulthood, persons with severe API defi-
ciency begin to develop emphysema due to
lack ofinhibition oflung connective tissue
degradation by neutrophil elastase and other
proteases. Even among never smokers, longi-
tudinal studies demonstrate excessive loss
(47-86 mL/year) ofFEV1 (146) compared
to historical controls (20-30 mL/year). As
discussed in detail later, emphysema develops
even more quickly in smokers with API defi-
ciency. The emphysema associated with API
deficiency has a pan-acinar pathologic pat-
tern, a feature distinguishing it from the cen-
trilobular pattern typical ofsmoking-induced
emphysema absent API deficiency (147).
Emphysema, when present in severe API
deficiency (Pi-Z), includes the lung bases in
the overwhelming majority of cases (142)
and has been suggested as a distinctive fea-
ture ofthis disorder.
Fewer than 1 in 1,600 U.S. Caucasians
and even fewer non-Caucasians are esti-
mated to have the Pi-ZZ genotype, so only a
small minority of cases of COPD can be
attributed to severe API deficiency related to
this genotype. There is continuing contro-
versy about the possibility that milder
degrees ofAPI deficiency, such as that asso-
ciated with the Pi-MZ genotype, may be
associated with increased risk ofdeveloping
chronic airflow obstruction. A number of
early studies suggested that the Pi-MZ geno-
type occurs in greater than expected fre-
quency among patients with emphysema
(148-152). A post mortem study found that
emphysema was more prevalent than
expected among those with mild API defi-
ciency (153). Some of these early studies,
however, inferred the API genotype from
serum API levels, which may have resulted
in misclassification of Pi-MZ and Pi-MM
patients (154). Case-control studies, as sum-
marized by Sandford et al. (155) have sug-
gested a 2- to 4-fold increased odds of
COPD in Pi-MZ heterozygotes.
In contrast to these case-control studies,
population-based studies have generally indi-
cated little association between the Pi-MZ
phenotype and impairment ofpulmonary
function when controlling forsmokingstatus.
Cross-sectional analysis of 143 Pi-MZ sub-
jects showed similar pulmonary function
(spirometry, diffusion, and lung volumes)
compared to matched controls (154). A
3-year longitudinal study ofPi-MZ patients
did not demonstrate excess decline ofFEV,
or FVC when compared to controls matched
for age, sex, height, race, and tobacco use
(143). These studies, however, are not with-
out limitations and it has been proposed that
Pi-MZ patients self-select away from expo-
sures that would result in impaired pul-
monary physiology (156). Other studies have
revealed subtle abnormalities ofpulmonary
function in association with the Pi-MZ geno-
type, including alterations in pressure/volume
curves (157).
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Even among persons with normal baseline
serum levels ofAPI, genetic variation impair-
ing the upregulation ofAPI during stress may
confer increased susceptibility to COPD. In
one study, a polymorphism in the 3' flanking
region ofthe API gene has been reported to
be present in 17% ofpatients with COPD
but in only 5% ofthe general population of
the United Kingdom (158). Although it is
not associated with abnormal API serum level
or function, it has been suggested that this
polymorphism lies within an enhancer
sequence and may impair the acute phase
increase inAPI expression (158,159).
Much less is known about the possible
role ofother protease inhibitor genes in the
pathogenesis of COPD. The protease
inhibitor aI-antichymotrypsin (ACT) is the
major physiologic inhibitor ofcathepsin G, an
elastolytic protease produced by neutrophils,
and has been observed to be protective against
pancreatitis-induced lung injury in rats (160).
The gene encoding ACT is located on chro-
mosome 14, in close proximity to the API
gene (161). Two mutations ofthe ACT gene
were identified in a screening study of200
COPD patients ofGerman extraction and
were associated in heterozygotes with a reduc-
tion in serum ACT activity to 62-75% of
normal (162,163). These mutations were pre-
sent in 1.5 and 4%, respectively, ofpatients
with COPD but in none of 100 control sub-
jects. This association of COPD and ACT
mutations was not duplicated in other trials
(164). X2-Macroglobulin is a serum nonspe-
cific antiprotease that appears in the sputum
during infections (165). Genetic variation in
the ACT structure has been associated with
premature lung disease (166,167), but these
findings have not been consistently replicated
and the role ofa2-macroglobulin in lung dis-
ease remains unclear (168). Other antipro-
teases, including serum leukoprotease
inhibitor and elafin, have been proposed as
playing a role in COPD pathogenesis (169),
but their importance in the development of
COPD remains speculative.
The hypothesis that an imbalance
between protease and antiprotease activity
plays a key role in COPD pathogenesis sug-
gests that genetically determined variations of
protease expression could predispose to or
protect from COPD. A knockout mouse
lacking macrophage metalloelastases does not
develop emphysema in response to tobacco
smoke exposure as do its wild-type counter-
parts (170). Conversely, a transgenic rat
expressing human collagenase has been
observed spontaneously to develop emphy-
sema (171). Patients with emphysema have
increased levels ofcollagenase (MMP-1) and
gelatinase-B (MMP-9), and have alveolar
macrophages that express more MMP-9 and
MMP-1 compared to controls (172). Other
proteases of potential importance in the
pathogenesis ofCOPD include other matrix
metalloproteinases and lysosomal cathepsins;
there are no data, however, to indicate that
genetics controlling the levels of these pro-
teases differ between emphysema patients and
controls. Additionally, there are no human
data linking mutations ofthe genes encoding
these proteases to the development ofCOPD.
Other immunologic factors have been
reported to be associated with COPD. One
study ofhuman leukocyte antigen expression
found a greater prevalence ofBw16 antigen
and a lower prevalence ofB7 antigen in per-
sons with COPD than in healthy controls
(173), although these findings have not been
reproduced. Various immunoglobulin defi-
ciencies ofIgG subtypes and IgA have been
described in association with COPD
(174-178). Vitamin D binding protein is a
multifunctional protein that, in addition to
binding vitamin D, enhances the effects of
chemotactic factors (179-182). Isoforms of
the protein have been found with decreased
(140) or increased frequency (183,184) in
COPD patients, although the results have
been inconsistent (173).
Avariety ofother mediators ofinflamma-
tion may play a role in the pathogenesis of
COPD, though the understanding of their
contributions remains in its infancy. The role
of lymphocyte response, and mediators
thereof, are under investigation. Lymphocytes
appear to respond through TH-1 (185)
mechanisms, and work on describing the
mediators of this response has begun
(186,187). Variation in certain mediators of
inflammation, including tumor necrosis fac-
tor alpha and interleukin (IL)-8 (188), have
also been found in COPD subpopulations,
and IL-4 receptor blockade has been associ-
ated with a reduction in neutrophil survival
(189). A positive association between pul-
monary surfactant and airways diameter has
been described; surfactant proteins were
observed to inhibit pulmonary inflammation
(190). Production of particular surfactant
proteins is inhibited by tobacco smoking
(191). Linking ofthese observations in the
pathogenesis ofCOPD has yet to be reported
As genetic polymorphisms influencing expres-
sion or function ofthese and other compo-
nents of the inflammatory cascade are
discovered, their possible roles in the differen-
tial sensitivities to the development ofCOPD
will be better understood.
An association between the presence of
blood type A and COPD has been reported
(192-194), but others have failed to confirm
this relationship (195,196). Many but not all
people secrete the ABO blood group antigen
into the upper and lower respiratory tract, and
secretor status has inconsistently been associ-
ated with airflow limitation (168,169,197).
Lewis blood group and Lewis antigen secretor
status have also been reported to be associated
with airflow limitation (198,199). In the
absence of a consistent association with
COPD, or a clear biologic rationale for such
an association, the roles, ifany, ofblood anti-
gen specificity and secretor status in the
pathogenesis ofCOPD remain uncertain.
Genetic factors likely affect susceptibility
to oxidative injury. Metabolic processes that
are upregulated in response to proinflamma-
tory stimulants (including electron transport
in the mitochondria, enzymatic activity such
as cyclooxygenase, and phagocytic activity in
the white blood cells) generate part of the
oxidative burden to the lung. Oxidants, as
discussed above, may then damage the air-
ways, resulting in chronic airflowobstruction.
Lower levels ofantioxidants have been corre-
lated with airflow obstruction (200). Urinary
excretion ofisoprostane2.III, a purported sta-
ble marker ofoxidative stress, is increased in
COPD patients (201). Microsomal epoxide
hydrolase (mEPHX), which detoxifies epox-
ides directly, has four described alleles.
Weakened defenses to oxidative stress may
occur through isomeric variation; Smith and
Harrison (202) described a higher frequency
of slow mEPHX enzyme among COPD
patients that may expose the lungs to unscav-
enged free radicals. Oxidative balance has
thus been implicated in the pathogenesis of
COPD, but the role ofthe host in generating
oxidative stress and balancing protective
mechanisms needs further investigation.
Gene-Environment Interactions
Tobacco smoke exposure is the strongest
environmental riskfactor forCOPD, but only
about 15% ofsmokers develop the disease
(52,203), and only 25-30% ofsmokers of30
pack-years or more develop clinically apparent
airflow obstruction (204,205). Even in the
presence ofsmall airways disease indicated by
a reduced FEF25-75 (forced expiratory flow
25-75% ofvital capacity), some smokers do
not develop clinically significant airflow
obstruction despite ongoing smoking for may
years (206). A recent family study compared
the lung function offirst-degree relatives of
probands with early-onset COPD, none of
whom had the Pi-ZZ genotype, to those of
persons without a family history of COPD
(207). Among nonsmokers, lung function was
similar between subjects with and without a
relative with COPD. Among cigarette smok-
ers, however, relatives ofa person with COPD
had a mean reduction of 13% in FEVi com-
pared to subjects without a family history of
smoking. These epidemiologic observations
suggest that host characteristics, including
genes, are important determinants ofsuscepti-
bility to airflow obstruction caused by
environmental factors such as tobacco smoke.
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The best-characterized example ofgene-
environment interaction in the pathogenesis
ofCOPD is the interaction between severe
API deficiency and tobacco smoking. As
described above, severe API deficiency in per-
sons with the Pi-ZZ genotype or other more
rare genotypes, is associated with the prema-
ture development of severe emphysema.
Among persons with severe API deficiency,
those who smoke tobacco experience a more
rapid rate of longitudinal lung function
decline and more severe airflow obstruction
than nonsmokers (146,208). A study from
Sweden demonstrated that only 50% of
Pi-ZZ smokers survived beyond 35 years of
age, whereas Pi-ZZ nonsmokers had a 50%
probability ofsurviving beyond age 57 (145).
The example ofgenetically determined
API deficiency predisposing to smoking-
induced chronic airflow obstruction provides
a paradigm ofgene-environment interaction,
consistent with current hypotheses concerning
the pathogenesis ofCOPD. In this model, an
inhaled environmental agent such as tobacco
smoke induces an inflammatory response in
the small airways that may result in irre-
versible damage to the small airways and cen-
trilobular alveoli. This damage is mediated by
proteolytic enzymes and oxygen free radicals,
and the degree ofdamage depends on geneti-
cally controlled systems that modulate the
inflammatory response and protect the lung
from proteolytic and oxidant injury.
Another example of possible gene-
environment interaction is the hypothesized
interaction between cigarette smoking and
the intermediate degree ofAPI deficiency
found in heterozygotes with the Pi-MZ
genotype. The putative role of the Pi-MZ
genotype in the pathogenesis of COPD
remains controversial; however, some reports
suggest the possibility of an interaction
between the Pi-MZ genotype and environ-
mental exposures. Abnormalities of pul-
monary function including abnormalities of
airflow have been observed in heterozygotes
who smoke (209,210) or have occupational
exposures (211), although the clinical signifi-
cance ofthese observations remains contro-
versial. Smokers with Pi-MZ have been
noted to have loss of elastic recoil, large
residual volume, and increased closing capac-
ity but not airflow obstruction (212). Grain
workers with the Pi-MZ genotype have been
reported to have a similar prevalence ofrespi-
ratory or atopic symptoms but more obstruc-
tive physiology than their Pi-MM
counterparts (211). In one study that
demonstrated subtle changes in pulmonary
function in association with the Pi-MZ phe-
notype, asubgroup analysis ofsix older heavy
smokers did not demonstrate a statistically
significant impact ofthe Pi-MZ phenotype
on spirometry (157).
Genetically controlled antioxidant defense
systems may also play an important role in
determiningsusceptibility, both to free radicals
released by inflammatory cells and to oxidants
inhaled from the environment. The lungs pos-
sess several antioxidant defense mechanisms,
including the reducing capabilities ofiron and
other metals, nonenzymatic antioxidants
(including vitamins E and C), and the enzy-
matic scavengers (including glutathione thiol,
superoxide dismutase, and microsomal epoxide
hydrolase), which are under genetic control.
The observations that the enzymatic antioxi-
dants are under genetic control and that allelic
variation alters their abilities to reduce free rad-
icals (213,214) suggest thatgenetic factors may
place some persons at greater risk for oxidant
injury. There is currently no direct evidence,
however, that specific genes related to antioxi-
dant defenses interact with environmental
factors to cause COPD.
Atopy, a genetically controlled trait, may
lead to airway inflammation and asthma in
genetically predisposed persons who are
exposed to environmental aeroallergens.
Asthma, in turn, appears to be a risk factor
for the development of irreversible airflow
obstruction that may ultimately be classified
as COPD. Asthma, as well as airways hyper-
reactivity in the absence ofasthma, has been
associated with an accelerated rate ofdecline
in FEV, (215-218), even after controlling
for tobacco use. Although asthma and
COPD are pathologically distinct (219),
chronic asthma may lead to some
histopathologic changes resembling COPD,
including inflammation with epithelial cell
loss, squamous metaplasia, leukocyte infiltra-
tion, basement membrane thickening (220),
as well as parenchymal destruction. The irre-
versible changes in airway histology seen in
chronic asthma are often referred to as "air-
way remodeling" (221). In addition, the
radiographic (222) and physiologic
(223,224) changes ofemphysema have been
noted in nonsmoking chronic asthmatics.
Chronic asthma can result in fixed airways
obstruction with loss ofelastic recoil and
expiratory flow, and with increased total lung
capacity. Although asthma is frequently asso-
ciated with an increased diffusion capacity
(224-229), a reduction in diffusing capacity
has also been noted in patients with no radi-
ographic evidence ofemphysema but who
have severe small airways disease (230).
Nonasthmatics with evidence ofallergy to
common aeroallergens have been reported to
have a more rapid rate oflongitudinal decline
in pulmonary function (216,218,231),
although conflicting data have been reported
(232). In addition, one report suggests that
exposure of sensitized persons to indoor
allergens may result in accelerated longitudi-
nal lung function decline even in the absence
ofasthma (218). The mechanisms by which
asthma, airways hyperreactivity, and atopy
lead to irreversible airways obstruction
remain to be determined, although chronic
airway inflammation provoked by environ-
mental allergens and the structural conse-
quences ofthis inflammation appear likely to
play an important role. The genetic mecha-
nisms ofatopy and asthma are currently the
focus of intensive investigation, and are
beyond the scope ofthis review.
Conclusion
Although tobacco smoking has been recog-
nized as the major environmental cause of
COPD for nearly halfa century, the elimina-
tion ofthis habit has been elusive. In addi-
tion, other environmental causes ofCOPD,
such as occupational dust exposure, have been
recognized. Although our understanding of
the cellular and biochemical pathogenesis of
COPD remains rudimentary, it is increas-
ingly evident that the host response to envi-
ronmental factors is subject to genetic
variation. The example ofAPI deficiency pro-
vides a clear example ofthe potential impor-
tance ofgene-environment interaction in the
pathogenesis of COPD, and the search for
additional gene products influencing COPD
risk is an area of active investigation.
However, API deficiency is the only known
single gene deficiency that results in COPD;
more commonly, it appears these host
responses to environmental stressors are
underpolygenic control.
Further research into the role of
gene-environment interaction in the develop-
ment ofCOPD must focus on several levels.
Improving our understanding ofthe molecu-
lar mechanisms causing COPD will allow
identification ofpossible target genes. Family
studies with linkage analysis and investigation
ofgene-environment interactions maylead to
the discovery ofgenetic polymorphisms that
influence the riskofdeveloping COPD.
The elucidation ofresponse mechanisms
maypermit the identification ofhigh-riskper-
sons who should be targeted for intensive
smoking-prevention or -cessation efforts and
who should avoid other environmental risk
factors. In addition, understanding these
mechanisms may lead to the development of
therapies that either alter the expression of
genes or augment or inhibit gene products to
reduce COPD risk. One example ofsuch a
therapy, augmentation therapy with purified
human API for patients with severe API defi-
ciency, has already been developed; future
research may lead to new preventative thera-
pies applicable to a larger proportion ofper-
sons who are at risk. The total elimination of
tobacco smoking, ofcourse, must remain the
primarypublic health focus for the prevention
ofCOPD.
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